Demographic, clinical, and MR imaging characteristics of patients at the time of 3T MR imaging
| Patients with RRMS (n = 9) | Patients with SPMS (n = 7) | P value* | |
|---|---|---|---|
| Age (y) | 41.3 ± 6.3 (range, 32–53) | 50.2 ± 6.0 (range, 41–56) | .012 |
| Sex | 5 women, 4 men | 6 women, 1 man | NS |
| Years since MS onset | 10.4 ± 6.2 (range, 3–20) | 18.4 ± 5.2 (range, 13–28) | .016 |
| EDSS | 1.9 ± 1.1 (range, 0–4) | 6.0 ± 0.6 (range, 5–6.5) | <.0001 |
| PASAT | 48.7 ± 12.8 (range, 22–60) | 31.2 ± 8.1 (range, 21–45) | .008 |
| BPF | 0.81 ± 0.05 (range, 0.76–0.92) | 0.75 ± 0.04 (range, 0.71–0.81) | .014 |
| T2-LV (cm3) | 11.5 ± 8.8 (range, 0.78–25.5) | 12.6 ± 8.4 (range, 4.6–30.1) | NS |
| Number of patients with CELs | 1† | 0 | N/A |
| CBHs (number) | 48.9 ± 51.5 (range, 0–126) | 37.4 ± 19.7 (range, 19–76) | NS |
| CBHs (volume in cm3) | 2.8 ± 3.3 (range, 0.1–9.6) | 3.2 ± 2.7 (range, 0.8–8.4) | NS |
| CBHs-LV/T2-LV (%) | 16.9 ± 11.7 (range, 3–34) | 24.1 ± 10.3 (range, 14–48) | NS |
| Undergoing therapies | |||
| Interferon beta | 3 | 3 | |
| Daclizumab | 4 | − | |
| Other treatments | − | 2 | |
| None | 2 | 2 |
Note:—RRMS indicates relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; EDSS, Expanded Disability Status Scale; PASAT, Paced Auditory Serial Addition Test; BPF, brain parenchyma fraction; T2-LV, T2 lesion volume; CELs, contrast-enhancing lesions; CBHs, chronic black holes; N/A, not applicable; NS, not significant.
* P values are significant if P ≤ .05.
† A single patient had 1 CEL in the corpus callosum (see text in the Results section).